Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial

BACKGROUND: In patients with COVID-19, granulocyte-macrophage colony stimulating factor (GM-CSF) might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death. We aimed to evaluate whether mavrilimumab, a monoclonal antibody to the GM-CSF receptor, would...

Descripción completa

Detalles Bibliográficos
Autores principales: Cremer, Paul C, Abbate, Antonio, Hudock, Kristin, McWilliams, Carla, Mehta, Jinesh, Chang, Steven Y, Sheng, Calvin C, Van Tassell, Benjamin, Bonaventura, Aldo, Vecchié, Alessandra, Carey, Brenna, Wang, Qiuqing, Wolski, Katherine E, Rajendram, Prabalini, Duggal, Abhijit, Wang, Tisha S, Paolini, John F, Trapnell, Bruce C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969143/
https://www.ncbi.nlm.nih.gov/pubmed/33754144
http://dx.doi.org/10.1016/S2665-9913(21)00070-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969143/
https://www.ncbi.nlm.nih.gov/pubmed/33754144
http://dx.doi.org/10.1016/S2665-9913(21)00070-9

Ejemplares similares